Annual EBIT
-$118.99 M
+$82.29 M+40.88%
31 December 2023
Summary:
Sangamo Therapeutics annual earnings before interest & taxes is currently -$118.99 million, with the most recent change of +$82.29 million (+40.88%) on 31 December 2023. During the last 3 years, it has risen by +$10.56 million (+8.15%). SGMO annual EBIT is now -37318.87% below its all-time high of -$318.00 thousand, reached on 31 December 1996.SGMO EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
$10.63 M
+$46.54 M+129.60%
30 September 2024
Summary:
Sangamo Therapeutics quarterly earnings before interest & taxes is currently $10.63 million, with the most recent change of +$46.54 million (+129.60%) on 30 September 2024. Over the past year, it has increased by +$72.24 million (+117.26%). SGMO quarterly EBIT is now -86.12% below its all-time high of $76.61 million, reached on 31 March 2023.SGMO Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$134.22 M
+$72.24 M+34.99%
30 September 2024
Summary:
Sangamo Therapeutics TTM earnings before interest & taxes is currently -$134.22 million, with the most recent change of +$72.24 million (+34.99%) on 30 September 2024. Over the past year, it has dropped by -$21.60 million (-19.18%). SGMO TTM EBIT is now -4714.24% below its all-time high of -$2.79 million, reached on 31 March 2000.SGMO TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SGMO EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +40.9% | +117.3% | -19.2% |
| 3 y3 years | +8.2% | +122.0% | +28.2% |
| 5 y5 years | -54.2% | +136.3% | -5.3% |
SGMO EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +40.9% | -86.1% | +114.7% | -69.0% | +44.7% |
| 5 y | 5 years | -54.2% | +40.9% | -86.1% | +114.7% | -69.0% | +44.7% |
| alltime | all time | <-9999.0% | +40.9% | -86.1% | +114.7% | -4714.2% | +44.7% |
Sangamo Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $10.63 M(-129.6%) | -$134.22 M(-35.0%) |
| June 2024 | - | -$35.91 M(-23.9%) | -$206.46 M(-15.0%) |
| Mar 2024 | - | -$47.18 M(-23.6%) | -$242.77 M(+104.0%) |
| Dec 2023 | -$118.99 M(-40.9%) | -$61.76 M(+0.2%) | -$118.99 M(+5.7%) |
| Sept 2023 | - | -$61.61 M(-14.7%) | -$112.62 M(+6.3%) |
| June 2023 | - | -$72.22 M(-194.3%) | -$105.91 M(+33.4%) |
| Mar 2023 | - | $76.61 M(-238.3%) | -$79.42 M(-60.5%) |
| Dec 2022 | -$201.28 M(+9.8%) | -$55.39 M(+0.9%) | -$201.28 M(+8.3%) |
| Sept 2022 | - | -$54.89 M(+20.0%) | -$185.79 M(+3.6%) |
| June 2022 | - | -$45.73 M(+1.0%) | -$179.33 M(-1.6%) |
| Mar 2022 | - | -$45.26 M(+13.4%) | -$182.30 M(-0.6%) |
| Dec 2021 | -$183.34 M(+41.5%) | -$39.90 M(-17.6%) | -$183.34 M(-1.9%) |
| Sept 2021 | - | -$48.44 M(-0.5%) | -$186.87 M(+31.5%) |
| June 2021 | - | -$48.70 M(+5.2%) | -$142.13 M(+8.2%) |
| Mar 2021 | - | -$46.30 M(+6.6%) | -$131.33 M(+1.4%) |
| Dec 2020 | -$129.55 M(+23.2%) | -$43.43 M(+1073.5%) | -$129.55 M(+53.0%) |
| Sept 2020 | - | -$3.70 M(-90.2%) | -$84.65 M(-23.2%) |
| June 2020 | - | -$37.90 M(-14.9%) | -$110.20 M(+4.2%) |
| Mar 2020 | - | -$44.52 M(-3130.8%) | -$105.81 M(+0.6%) |
| Dec 2019 | -$105.18 M(+36.3%) | $1.47 M(-105.0%) | -$105.18 M(-17.5%) |
| Sept 2019 | - | -$29.25 M(-12.7%) | -$127.42 M(+11.4%) |
| June 2019 | - | -$33.50 M(-23.7%) | -$114.41 M(+14.4%) |
| Mar 2019 | - | -$43.90 M(+111.3%) | -$100.05 M(+29.7%) |
| Dec 2018 | -$77.15 M(+36.9%) | -$20.77 M(+27.9%) | -$77.15 M(+10.0%) |
| Sept 2018 | - | -$16.24 M(-15.1%) | -$70.14 M(+4.8%) |
| June 2018 | - | -$19.14 M(-8.8%) | -$66.94 M(+10.5%) |
| Mar 2018 | - | -$21.00 M(+52.5%) | -$60.57 M(+7.5%) |
| Dec 2017 | -$56.36 M(-22.3%) | -$13.77 M(+5.6%) | -$56.36 M(+7.5%) |
| Sept 2017 | - | -$13.04 M(+2.1%) | -$52.42 M(-10.5%) |
| June 2017 | - | -$12.77 M(-24.0%) | -$58.60 M(-19.4%) |
| Mar 2017 | - | -$16.79 M(+70.8%) | -$72.67 M(+0.2%) |
| Dec 2016 | -$72.56 M(+54.9%) | -$9.83 M(-48.8%) | -$72.56 M(-7.5%) |
| Sept 2016 | - | -$19.21 M(-28.4%) | -$78.40 M(+9.1%) |
| June 2016 | - | -$26.84 M(+60.9%) | -$71.88 M(+25.4%) |
| Mar 2016 | - | -$16.68 M(+6.4%) | -$57.32 M(+22.3%) |
| Dec 2015 | -$46.86 M(+75.0%) | -$15.67 M(+23.6%) | -$46.86 M(+31.4%) |
| Sept 2015 | - | -$12.69 M(+3.3%) | -$35.65 M(+16.4%) |
| June 2015 | - | -$12.28 M(+97.3%) | -$30.62 M(+20.6%) |
| Mar 2015 | - | -$6.22 M(+39.2%) | -$25.39 M(-5.2%) |
| Dec 2014 | -$26.78 M(+0.3%) | -$4.47 M(-41.6%) | -$26.78 M(-12.2%) |
| Sept 2014 | - | -$7.65 M(+8.6%) | -$30.49 M(+5.2%) |
| June 2014 | - | -$7.05 M(-7.4%) | -$28.99 M(+5.8%) |
| Mar 2014 | - | -$7.61 M(-6.9%) | -$27.41 M(+2.6%) |
| Dec 2013 | -$26.71 M(+20.3%) | -$8.17 M(+32.7%) | -$26.71 M(+21.9%) |
| Sept 2013 | - | -$6.16 M(+12.6%) | -$21.90 M(+1.7%) |
| June 2013 | - | -$5.47 M(-20.8%) | -$21.54 M(-1.3%) |
| Mar 2013 | - | -$6.91 M(+105.0%) | -$21.82 M(-1.7%) |
| Dec 2012 | -$22.20 M(-38.0%) | -$3.37 M(-41.9%) | -$22.20 M(-11.9%) |
| Sept 2012 | - | -$5.80 M(+1.0%) | -$25.19 M(-13.0%) |
| June 2012 | - | -$5.74 M(-21.1%) | -$28.97 M(-13.5%) |
| Mar 2012 | - | -$7.28 M(+14.4%) | -$33.50 M(-6.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | -$35.82 M(+43.7%) | -$6.37 M(-33.5%) | -$35.82 M(-5.2%) |
| Sept 2011 | - | -$9.57 M(-6.9%) | -$37.79 M(+2.3%) |
| June 2011 | - | -$10.28 M(+7.1%) | -$36.94 M(+21.0%) |
| Mar 2011 | - | -$9.60 M(+15.1%) | -$30.53 M(+22.5%) |
| Dec 2010 | -$24.93 M(+28.5%) | -$8.34 M(-4.3%) | -$24.93 M(+31.2%) |
| Sept 2010 | - | -$8.71 M(+124.7%) | -$19.01 M(+25.9%) |
| June 2010 | - | -$3.88 M(-3.1%) | -$15.10 M(-7.8%) |
| Mar 2010 | - | -$4.00 M(+65.8%) | -$16.38 M(-15.6%) |
| Dec 2009 | -$19.40 M(-23.5%) | -$2.42 M(-49.7%) | -$19.40 M(+1.1%) |
| Sept 2009 | - | -$4.80 M(-6.9%) | -$19.19 M(-7.6%) |
| June 2009 | - | -$5.16 M(-26.6%) | -$20.76 M(-12.0%) |
| Mar 2009 | - | -$7.03 M(+219.5%) | -$23.59 M(-7.0%) |
| Dec 2008 | -$25.38 M(+2.4%) | -$2.20 M(-65.5%) | -$25.38 M(-17.6%) |
| Sept 2008 | - | -$6.38 M(-20.1%) | -$30.79 M(+3.6%) |
| June 2008 | - | -$7.99 M(-9.3%) | -$29.72 M(+7.8%) |
| Mar 2008 | - | -$8.81 M(+15.8%) | -$27.57 M(+11.3%) |
| Dec 2007 | -$24.77 M(+19.5%) | -$7.61 M(+43.0%) | -$24.77 M(-8.2%) |
| Sept 2007 | - | -$5.32 M(-8.9%) | -$26.97 M(+6.6%) |
| June 2007 | - | -$5.84 M(-2.8%) | -$25.29 M(+7.5%) |
| Mar 2007 | - | -$6.01 M(-38.7%) | -$23.53 M(+13.5%) |
| Dec 2006 | -$20.73 M(+50.8%) | -$9.81 M(+169.2%) | -$20.73 M(+49.7%) |
| Sept 2006 | - | -$3.64 M(-10.5%) | -$13.84 M(-1.1%) |
| June 2006 | - | -$4.07 M(+26.9%) | -$13.99 M(+4.6%) |
| Mar 2006 | - | -$3.21 M(+9.9%) | -$13.38 M(-2.7%) |
| Dec 2005 | -$13.75 M(-6.2%) | -$2.92 M(-23.0%) | -$13.75 M(-3.4%) |
| Sept 2005 | - | -$3.79 M(+9.7%) | -$14.23 M(-5.8%) |
| June 2005 | - | -$3.46 M(-3.5%) | -$15.11 M(+83.0%) |
| Mar 2005 | - | -$3.58 M(+5.3%) | -$8.26 M(+5.1%) |
| Dec 2004 | -$14.65 M(+24.5%) | -$3.40 M(-27.3%) | -$7.86 M(+21.1%) |
| Sept 2004 | - | -$4.67 M(-237.6%) | -$6.49 M(+35.8%) |
| June 2004 | - | $3.40 M(-206.9%) | -$4.78 M(-59.8%) |
| Mar 2004 | - | -$3.18 M(+56.7%) | -$11.88 M(+0.9%) |
| Dec 2003 | -$11.77 M(-62.3%) | -$2.03 M(-31.6%) | -$11.77 M(+9.2%) |
| Sept 2003 | - | -$2.97 M(-19.9%) | -$10.78 M(-63.1%) |
| June 2003 | - | -$3.70 M(+20.6%) | -$29.23 M(-0.9%) |
| Mar 2003 | - | -$3.07 M(+196.7%) | -$29.50 M(-5.4%) |
| Dec 2002 | -$31.19 M(+102.8%) | -$1.03 M(-95.2%) | -$31.19 M(-8.6%) |
| Sept 2002 | - | -$21.42 M(+438.6%) | -$34.13 M(+91.3%) |
| June 2002 | - | -$3.98 M(-16.5%) | -$17.84 M(+4.2%) |
| Mar 2002 | - | -$4.76 M(+19.8%) | -$17.12 M(+11.3%) |
| Dec 2001 | -$15.38 M(+23.2%) | -$3.97 M(-22.5%) | -$15.38 M(+0.6%) |
| Sept 2001 | - | -$5.13 M(+57.5%) | -$15.28 M(+15.3%) |
| June 2001 | - | -$3.25 M(+7.7%) | -$13.26 M(+4.3%) |
| Mar 2001 | - | -$3.02 M(-22.0%) | -$12.72 M(+1.9%) |
| Dec 2000 | -$12.48 M(+220.1%) | -$3.88 M(+24.9%) | -$12.48 M(+45.1%) |
| Sept 2000 | - | -$3.10 M(+14.5%) | -$8.61 M(+56.5%) |
| June 2000 | - | -$2.71 M(-2.7%) | -$5.50 M(+97.3%) |
| Mar 2000 | - | -$2.79 M | -$2.79 M |
| Dec 1999 | -$3.90 M(+12.8%) | - | - |
| Dec 1998 | -$3.46 M(+157.1%) | - | - |
| Dec 1997 | -$1.34 M(+323.0%) | - | - |
| Dec 1996 | -$318.00 K | - | - |
FAQ
- What is Sangamo Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Sangamo Therapeutics?
- What is Sangamo Therapeutics annual EBIT year-on-year change?
- What is Sangamo Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Sangamo Therapeutics?
- What is Sangamo Therapeutics quarterly EBIT year-on-year change?
- What is Sangamo Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Sangamo Therapeutics?
- What is Sangamo Therapeutics TTM EBIT year-on-year change?
What is Sangamo Therapeutics annual earnings before interest & taxes?
The current annual EBIT of SGMO is -$118.99 M
What is the all time high annual EBIT for Sangamo Therapeutics?
Sangamo Therapeutics all-time high annual earnings before interest & taxes is -$318.00 K
What is Sangamo Therapeutics annual EBIT year-on-year change?
Over the past year, SGMO annual earnings before interest & taxes has changed by +$82.29 M (+40.88%)
What is Sangamo Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of SGMO is $10.63 M
What is the all time high quarterly EBIT for Sangamo Therapeutics?
Sangamo Therapeutics all-time high quarterly earnings before interest & taxes is $76.61 M
What is Sangamo Therapeutics quarterly EBIT year-on-year change?
Over the past year, SGMO quarterly earnings before interest & taxes has changed by +$72.24 M (+117.26%)
What is Sangamo Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of SGMO is -$134.22 M
What is the all time high TTM EBIT for Sangamo Therapeutics?
Sangamo Therapeutics all-time high TTM earnings before interest & taxes is -$2.79 M
What is Sangamo Therapeutics TTM EBIT year-on-year change?
Over the past year, SGMO TTM earnings before interest & taxes has changed by -$21.60 M (-19.18%)